Phase I single-ascending dose study of ASKP1240 (Anti-CD40 MAB) in healthy subjects.

Trial Profile

Phase I single-ascending dose study of ASKP1240 (Anti-CD40 MAB) in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Bleselumab (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Dec 2012 Additional lead trial centre (Kyowa Hakko Kirin) added as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Actual initiation date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top